Search research articles
Contact Us
Filters
Showing results (301-310 of 438) with videos related to
Page
of 44
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2016
Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer
Suresh S Ramalingam, Normand Blais, Julien Mazieres, et al.
General Hospital Psychiatry
|
March 19, 2025
Existential distress in advanced cancer: A cohort study
Rebecca Philipp, Charlotte Walbaum, Uwe Koch, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 27, 2026
Spatial proteomics profiling reveals oncogene-specific immune niches and prognostic markers in NSCLC
Rajender Nandigama, Bassem Ben Cheikh, Jochen Wilhelm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2017
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
Federica Grosso, Nicola Steele, Silvia Novello, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 26, 2021
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
Mark A Socinski, Makoto Nishio, Robert M Jotte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer
Mark A Socinski, Egbert F Smit, Paul Lorigan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 25, 2023
Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial
Martin Reck, Fabrice Barlesi, James Chih-Hsin Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2016
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
Martin Reck, Alexander Luft, Aleksandra Szczesna, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 21, 2009
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer
Giorgio V Scagliotti, Paul Germonpré, Leon Bosquée, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2021
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, et al.
Page
of 44
Search research articles
Search
Showing results (301-310 of 438) with videos related to
Sort By:
Page
of 44
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2016
Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer
Suresh S Ramalingam, Normand Blais, Julien Mazieres, et al.
General Hospital Psychiatry
|
March 19, 2025
Existential distress in advanced cancer: A cohort study
Rebecca Philipp, Charlotte Walbaum, Uwe Koch, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 27, 2026
Spatial proteomics profiling reveals oncogene-specific immune niches and prognostic markers in NSCLC
Rajender Nandigama, Bassem Ben Cheikh, Jochen Wilhelm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2017
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
Federica Grosso, Nicola Steele, Silvia Novello, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 26, 2021
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
Mark A Socinski, Makoto Nishio, Robert M Jotte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer
Mark A Socinski, Egbert F Smit, Paul Lorigan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 25, 2023
Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial
Martin Reck, Fabrice Barlesi, James Chih-Hsin Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2016
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
Martin Reck, Alexander Luft, Aleksandra Szczesna, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 21, 2009
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer
Giorgio V Scagliotti, Paul Germonpré, Leon Bosquée, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2021
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, et al.
Page
of 44